• The Kogan share price is surging higher following another positive business update

    shopping trolley next to laptop, asx 200 retail shares, kogan share price

    The Kogan.com Ltd (ASX: KGN) share price is surging higher this morning following another strong business update.

    Kogan has provided the market with an update of how it has performed during the fourth quarter to date, in light of the coronavirus crisis.

    The Kogan share price has been experiencing a very strong rally in recent months. Kogan shares dropped to a low of $3.45 in mid-March but closed yesterday at $11.40. That’s a massive 230% increase. The rally has been particularly strong since mid-May and appears set to continue based on morning trade today. At the time of writing, Kogan’s share price has already climbed nearly 9% since the market opened.

    The S&P/ASX 200 Index (ASX: XJO) in comparison, has seen a much more modest recovery since the March crash.

    Customer base and sales continue their upward trajectory

    Kogan revealed today that its active customer base has continued on a strong growth trajectory. There were an additional 126,000 active customers added during May to now total 2,074,000. That’s an increase of 6.5%.

    Gross sales for Kogan soared higher by more than 100% in the fourth quarter to date (April and May), compared to the equivalent period in 2019.

    Kogan previously revealed to the market that the pipeline for new sellers in its Kogan Marketplace remains very strong. This is helping to boost the company’s strong sales momentum and, as such, the Kogan share price.

    Profitability continues to climb

    Kogan’s profitability also continues to improve. The company’s gross profit increased by more than 130% during April and May.

    EBITDA growth was even more impressive. Adjusted EBITDA climbed by more than 200% in the prior two months, compared to the corresponding period.

    When EBITDA is adjusted for the financial year to date, it grew by more than 50%. Also, a very impressive result.

    Kogan’s strong growth during the last two month follows on from a very strong March quarter. The Aussie ‘etailer’ revealed back then a strong 30% increase in gross sales and a 23% jump in gross profit during the March quarter.

    There has been a sharp increase in spending at online retail sites such as Kogan and Amazon since lockdown restrictions were implemented. With more Australians working from home, Kogan has been cashing in on strong demand for goods such as PCs and laptops. Also, other home office accessories as well as home fitness equipment have proven very popular with Aussies isolating at home. Whilst many companies have suffered significant revenue losses due to the COVID-19 crisis, the pandemic has largely been good news for the Kogan share price.

    Where to next for the Kogan share price?

    In more good news, Kogan also revealed today that it ended the month of May with $58.6 million of cash on its books. The company also has a debt facility which was drawn to $26.0 million. So, its cash position is fairly solid. As mentioned, Kogan’s share price is up by another massive 9% to be trading at $12.41. However, with such a strong rally since mid-March, I feel that Kogan may see some high share price volatility in the months ahead.

    Not liking the look of Kogan? Check out the following potential growth shares instead.

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Motley Fool contributor Phil Harpur owns shares of Kogan.com ltd. The Motley Fool Australia owns shares of and has recommended Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post The Kogan share price is surging higher following another positive business update appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/374wuBb

  • Seanergy’s Shipping Rates Set to Rebound While Equity Raises Will Reduce Debt, Says Analyst

    Seanergy’s Shipping Rates Set to Rebound While Equity Raises Will Reduce Debt, Says AnalystTaking the term penny stock to a whole new level, we have Seanergy Maritime (SHIP). Shares are going for $0.12 apiece following another year of massive share price depreciation. The stock is down by 78% so far in 2020. Zoom out by five years and add in bouts of shareholder dilution, and the stock is only 0.25% away from a 100% decline.However, not all hope is lost. In fact, Maxim analyst Tate Sullivan remains firmly in the shipping company’s corner.Sullivan has a Buy rating on Seanergy based on his “outlook for SHIP to use recent equity proceeds to reduce and/or extend debt maturities, as well as our forecast for an eventual rebound in international shipping activity and higher rates.”Having said that, the decline in shipping rates means the price target is reduced from $0.40 to $0.30. Despite the trim, the potential upside from current levels is a lofty 120%. (To watch Sullivan’s track record, click here)After equity was raised through four public offerings in Q1 – amounting to roughly $25 million – Seanergy recently disclosed that over the last two weeks, it raised another $9.9 million from warrant exercises.Sullivan believes the proceeds will go towards further reducing debt, and forecasts debt of $196.8 million by the end of the year – down from the prior estimate of $206.3 million. Looking ahead, the analyst is optimistic, expecting “continued debt paydown in 2020.”“We estimate SHIP will reduce debt by $28.7 million in 2Q20. Our forecast includes the use of net proceeds from equity raises of $36.8 million (our estimate). In addition, we forecast debt reduction of $8.8 million in the second half of 2020 based on generating free cash flow,” said Sullivan.It should be noted that the Baltic Capesize Index has been particularly volatile in 2020, increasing by more than 370% in April as factory and port activity in China ramped up after COVID-19 lockdown measures were loosened. The index then dropped sharply in May, falling 66% from the previous month, mainly because of lower international demand for iron ore.Additionally, iron ore exports from Brazil, one of the world’s current COVID-19 hotspots, could experience further delays as a result of the pandemic. That said, Sullivan expects things to pick up later in the year.“We continue to forecast a rebound in rates after 2Q20, but from a slightly lower base,” the analyst concluded.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * 3 Under-The-Radar Cannabis Stocks Ready to Bounce * Ebay Lifts Quarterly Sales and Profit Forecast; Shares Jump To All-Time High * 3 “Strong Buy” Penny Stocks That Could See Outsized Returns * Amazon Is Mulling To Buy $2 Billion Stake In Indian Telecom Bharti Airtel

    from Yahoo Finance https://ift.tt/2AETo6k

  • Why Kogan, NAB, Qantas, & Sydney Airport shares are racing higher

    shares higher

    In late morning trade the S&P/ASX 200 Index (ASX: XJO) is fighting hard to get into positive territory. At the time of writing the benchmark index is down 0.2% to 5,980.7 points.

    Four shares that have not let that hold them back are listed below. Here’s why they are racing higher:

    The Kogan.com Ltd (ASX: KGN) share price has jumped 9% to $12.42. Investors have been buying the ecommerce company’s shares after it released a business update. That update revealed that Kogan’s impressive customer, sales, and profit growth continued during the month of May. The company added 126,000 active customers during May. This helped more than double its sales and triple its operating earnings quarter to date.

    The National Australia Bank Ltd (ASX: NAB) share price is up 2% to $19.28. The banking giant’s shares were given a big boost this morning by a broker note out of UBS. It has upgraded NAB’s shares to a buy rating with a $20.50 price target. It doesn’t feel that NAB’s outlook is as bleak as first feared.

    The Qantas Airways Limited (ASX: QAN) share price has continued its positive run and is up a further 3% to $4.63. Investors have been buying the airline operator’s shares after it announced an increase in domestic flights for June and July. By the end of July, subject to demand, Qantas’ domestic capacity could be 40% of pre-pandemic levels. This morning Morgan Stanley responded to the news by retaining its buy rating and $5.20 price target. 

    The Sydney Airport Holdings Pty Ltd (ASX: SYD) share price has pushed over 4% higher to $6.36. This gain appears to have been driven by the aforementioned news out of Qantas. A quicker than expected recovery in domestic tourism would be a big positive for Sydney Airport and limit the cash burn it is currently experiencing.

    Missed out on these gains? Then don’t miss out on the highly rated shares which are recommended below…

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why Kogan, NAB, Qantas, & Sydney Airport shares are racing higher appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3eSeDAh

  • SCYNEXIS Inc (SCYX): Are Hedge Funds Right About This Stock?

    SCYNEXIS Inc (SCYX): Are Hedge Funds Right About This Stock?In this article we will take a look at whether hedge funds think SCYNEXIS Inc (NASDAQ:SCYX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

    from Yahoo Finance https://ift.tt/3cxh7Cr

  • Top broker tips the Vocus share price to zoom higher

    Buy ASX shares

    The Vocus Group Ltd (ASX: VOC) share price has been an impressive performer over the last two and a half months.

    Since the specialist fibre and network solutions provider’s shares fell to a 52-week low of $1.80 in late March, they have rallied a massive 73% to trade at $3.13 today.

    Is it too late to buy Vocus shares?

    The Vocus share price can still go a lot higher from here according to one leading broker.

    A note out of Goldman Sachs this morning reveals that its analysts have reiterated their buy rating and $3.85 price target on the company’s shares.

    This price target implies potential upside of 23% for its shares over the next 12 months.

    Why is Goldman Sachs bullish?

    According to the note, the broker was pleased to see Vocus reiterate its FY 2020 guidance and announce the refinancing of its debt on Thursday.

    Vocus revealed that it expects its FY 2020 earnings before interest, tax, depreciation, and amortisation (EBITDA) to be in the range of $359 million to $369 million.

    This compares to the EBITDA of $356 million that Goldman was expecting. It believes this is reflective of the resilience of telecom earnings.

    Overall, the broker remains positive on its outlook and also on its valuation in comparison to rival TPG Telecom Ltd (ASX: TPM).

    Goldman commented: “We stay Buy on Vocus with this update removing two key investor issues (i.e. refinancing & lack of guidance commentary) and helping to de-risk our positive investment view.”

    “This is based on: (1) improving Enterprise earnings outlook, with a meaningful opportunity to partner with NBN Co.; (2) favorable valuation (vs. TPM and history); (3) significant infrastructure asset base, which we see as attractive in a low-rate environment,” it concluded.

    Should you buy Vocus shares?

    While my preference in the telco space remains Telstra Corporation Ltd (ASX: TLS), I think Vocus is a great option as well.

    Times have been hard for the company over the last few years, but it finally appears to be on track now to deliver solid growth over the coming years. This could lead to the Vocus share price outperforming over the medium term.

    And here are more top shares which analysts have just given buy ratings to…

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Telstra Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Top broker tips the Vocus share price to zoom higher appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2UcSuVw

  • Moderna’s (MRNA) Stock Will Surge 80% From Current Levels, Says Analyst

    Moderna’s (MRNA) Stock Will Surge 80% From Current Levels, Says AnalystThere’s no doubt about it, Moderna’s (MRNA) profile has increased dramatically since the pandemic’s onset.The biotech name has climbed 206% higher this year, as investors have piled in with the hope that its COVID-19 vaccine candidate, mRNA-1273, might be the one to solve the coronavirus conundrum. Yet, it hasn’t all been positive news. Recently, questions have surfaced concerning the company’s sale of shares following the stock’s latest surge.Blocking out all of the noise, Oppenheimer analyst Hartag Singh recently attended Moderna’s virtual Science Day to get some visibility on the work going on behind the scenes. The 5-star analyst liked what he heard, to say the least.“Building on the last two Science Days, Moderna has kept a focus on strengthening its Research Platform science, with (1) increasing mRNA and encoded protein half-lives and stabilizing mRNA while avoiding double-stranded RNA impurities, (2) making a novel squaramide-based ionizable lipid (new LNP) to improve protein expression, and (3) designing a preclinical HIV vaccine program to MRNA's platform with its rapid iterative design/testing abilities,” Singh said.Highlights from the presentation included information regarding protein half-lives; Singh notes the duration of response and protein expression is improved by increasing half-lives of mRNA and protein. This is accomplished by “maximizing secondary structure and codon optimality, with a terminal idT added to prevent deadenylation that causes mRNA decay.”Singh added, “On a broader level, being able to understand and govern half-lives could potentially open new indication opportunities as well as better products for life-cycle management.”Moderna’s research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to develop an HIV vaccine also got a mention, with MRNA's “unique platform capabilities,” receiving plaudits from both presenting KOLs (key opinion leaders).Summarizing, Singh “stays bullish,” and further said, “We would like to remind investors that MRNA's story is not a linear one but a platform expanding its value from many aspects.”To this end, Singh reiterated an Outperform rating on Moderna shares along with a $108 price target. Investors could be in for nearly 80% gain, should the Oppenheimer analyst’s thesis play out over the next year. (To watch Singh’s track record, click here)The rest of the Street keeps a bullish stance on Moderna, too. 10 Buys and 2 Holds add up to a Strong Buy consensus rating. The average price target comes in at $89.33, and implies possible upside of a handsome 47%. (See Moderna stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/2BA6ulL

  • Hedge Funds Warming Up To Clearside Biomedical, Inc. (CLSD) Again?

    Hedge Funds Warming Up To Clearside Biomedical, Inc. (CLSD) Again?Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

    from Yahoo Finance https://ift.tt/3gXEbxC

  • Atomo Diagnostics share price charges higher on expanded COVID-19 testing partnership

    Stylised portrayal of virus outbreak on blue background

    The Atomo Diagnostics Ltd (ASX: AT1) share price is charging higher this morning after expanding its COVID-19 testing partnership with a French biotech company.

    Atomo Diagnostics is a medical device company that supplies rapid diagnostic test (RDT) devices to the global diagnostic market. Its RDT platforms simplify testing procedures and enhance usability for both professional users and untrained self-testers. The company has supply agreements in place for tests targeting infectious diseases such as HIV and COVID-19.

    Atomo Diagnostics shares are fresh on the ASX scene after listing on 16 April 2020 at an issue price of 20 cents per share. At the time of writing, Atomo Diagnostics shares are changing hands at 34.5 cents per share – 9.52% higher for the day and 72.5% higher than the IPO price. The company’s market capitalisation is currently sitting just below $200 million.

    What did Atomo Diagnostics announce?

    After the market closed yesterday, Atomo revealed it has expanded its COVID-19 rapid test partnership with NG Biotech.

    Under the existing agreement, Atomo has been supplying NG Biotech with its Galileo rapid test device for use in NG Biotech’s COVID-19 antibody tests. The initial order under the agreement was for 397,200 devices, with NG Biotech having the right to purchase up to 2.465 million devices.

    To date, NG Biotech has ordered more than 1.5 million Galileo devices for testing in France. NG Biotech’s test has been CE Marked for professional use in Europe and results are obtained from a drop of blood in 15 minutes.

    Under the expansion of the partnership, Atomo now has exclusive rights to market and distribute the COVID-19 antibody test in Australia, New Zealand, and a number of countries in South East Asia – subject to obtaining regulatory approvals in each jurisdiction. The test will be marketed and distributed under the brand ‘AtomoRapid COVID-19 (IgG/IgM)’ and Atomo will be the listed manufacturer.

    The pricing arrangements with NG Biotech are limited to a price payable per unit only and do not include any license fees or royalties.

    Atomo noted that the period of exclusivity is not currently limited and it is in the process of negotiating a definitive long-term supply agreement with NG Biotech.

    What now?

    Atomo will now progress regulatory applications within the relevant jurisdictions in the coming months. Based on an assessment of regulatory pathways, the company’s initial focus will be Australia, the Philippines, Hong Kong and Taiwan.

    Commenting on the partnership expansion, Atomo’s co-founder and managing director John Kelly said:

    “Atomo is delighted to have secured exclusive rights to market, as the listed manufacturer, the COVID19 test which NG Biotech has successfully launched in Europe with initial sales to the French Ministry of the Armies (Defence) and a number of public hospitals, following strong results in independent French clinical studies.”

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Atomo Diagnostics share price charges higher on expanded COVID-19 testing partnership appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3gXTYwo

  • Is VBI Vaccines, Inc. (VBIV) A Good Stock To Buy?

    Is VBI Vaccines, Inc. (VBIV) A Good Stock To Buy?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

    from Yahoo Finance https://ift.tt/3cG5Ujm

  • Is the Westpac share price too high?

    Holding piggy bank in hands, long term shares, shares to buy and hold

    The Westpac Banking Corp (ASX: WBC) share price had another strong day yesterday, surging 1.28% to $18.18 per share.

    While the S&P/ASX 200 Index (ASX: XJO) edged 0.84% higher, Westpac was one of the ASX 200 shares leading the way.

    At the time of writing, shares in the Aussie bank were up 5.57% this week, but are they overvalued today?

    Is the Westpac share price overvalued?

    The ASX bank shares have been on a rollercoaster ride in 2020. The Westpac share price slumped as low as $13.47 in mid-March amid the bear market.

    There’s been a strong rebound since, despite weak economic data and Australia heading towards a recession. But Westpac may no longer be the bargain buy it once was. 

    Many, including Westpac, announced billions of dollars of impairments in April and May due to COVID-19. However, loan quality may not deteriorate if the economy bounces back quicker than expected.

    But all of this seems to ignore the impending recession and its impact on the Aussie economy. The share market is inherently forward-looking but I don’t think all economic impacts are fully priced in.

    There’s a lot of cash flying around in markets right now. With interest rates sitting as little as 0.25%, not many people like the idea of savings accounts or bonds for a strong return.

    That means you could look towards ASX shares. The Westpac share price is still a long way down from its $30.05 52-week high. It’s been a big 12 months for the Aussie bank highlighted by its AUSTRAC scandal and the subsequent fallout.

    Foolish takeaway

    I still think the Westpac share price could climb higher and surpass $20 per share in 2020. There could be more volatility ahead, but that’s not necessarily a bad thing if you’re a long-term investor who is willing to buy and hold.

    For more ASX shares trading at a good price, check out these 5 cheap shares today!

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Is the Westpac share price too high? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3dMv417